Genome-wide polygenic risk scores predict risk of glioma and molecular subtypes
Authors:
- Taishi NakaseTNTaishi Nakase
- Geno A GuerraGGGeno A Guerra
- Glioma International Case-Control Study (GICC)G(Glioma International Case-Control Study (GICC)
- 25 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (10) , 1933-1944
Abstract
Background: Polygenic risk scores (PRS) aggregate the contribution of many risk variants to provide a personalized genetic susceptibility profile. Since sample sizes of glioma genome-wide association studies (GWAS) remain modest, there is a need to efficiently capture genetic risk using available data. Methods: We applied a method based on continuous shrinkage priors (PRS-CS) to model the joint effects of over 1 million common variants on disease risk and compared this to an approach (PRS-CT) that only selects a limited set of independent variants that reach genome-wide significance (P < 5 × 10–8). PRS models were trained using GWAS stratified by histological (10 346 cases and 14 687 controls) and molecular subtype (2632 cases and 2445 controls), and validated in 2 independent cohorts. Results: PRS-CS was generally more predictive than PRS-CT with a median increase in explained variance (R2) of 24% (interquartile range = 11–30%) across glioma subtypes. Improvements were pronounced for glioblastoma (GBM), with PRS-CS yielding larger odds ratios (OR) per standard deviation (SD) (OR = 1.93, P = 2.0 × 10–54 vs. OR = 1.83, P = 9.4 × 10–50) and higher explained variance (R2 = 2.82% vs. R2 = 2.56%). Individuals in the 80th percentile of the PRS-CS distribution had a significantly higher risk of GBM (0.107%) at age 60 compared to those with average PRS (0.046%, P = 2.4 × 10–12). Lifetime absolute risk reached 1.18% for glioma and 0.76% for IDH wildtype tumors for individuals in the 95th PRS percentile. PRS-CS augmented the classification of IDH mutation status in cases when added to demographic factors (AUC = 0.839 vs. AUC = 0.895, PΔAUC = 6.8 × 10–9). Conclusions: Genome-wide PRS has the potential to enhance the detection of high-risk individuals and help distinguish between prognostic glioma subtypes.Keywords
All Related Versions
Funding Information
- National Institutes of Health (T32CA151022, R01CA266676, R01CA52689, P50CA097257, R01CA126831, R01CA139020, R01AI128775, R25CA112355)
- LoGlio Collective
- National Brain Tumor Foundation
- Stanley D. Lewis, and Virginia S. Lewis Endowed Chair in Brain Tumor Research
- Robert Magnin Newman Endowed Chair in Neuro-oncology
- National Center for Research Resources
- National Center for Advancing Translational Sciences
- California Department of Public Health
- Centers for Disease Control and Prevention (5NU58DP006344)
- The National Cancer Institute (HHSN261201800032I, HHSN261201800015I, HHSN261201800009I)
- US NIH (R01CA139020, R01CA52689)
- National Institute of Health (UL1 RR024131, R00CA246076, U01CA261339, U01HG011723, R01CA232754, 5P30CA082103)
- National Institute of Health (CA230712, P50 CA108961, CA139020)
- National Brain Tumor Society
- LoGlio Collective
- Mayo Clinic
- Ting Tsung and Wei Fong Chao Foundation
- UCSF Neurosurgery Tissue Bank
This publication has 46 references indexed in Scilit:
- Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendantsInternational Journal of Cancer, 2020
- On the estimation of average treatment effects with right‐censored time to event outcome and competing risksBiometrical Journal, 2020
- Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysisEuropean Radiology, 2018
- Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implicationsCancer, 2017
- Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRIMagnetic Resonance in Medicine, 2017
- Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERTActa Neuropathologica, 2017
- History of chickenpox in glioma risk: a report from the glioma international case–control study (GICC)Cancer Medicine, 2016
- Reclassification of predictions for uncovering subgroup specific improvementStatistics in Medicine, 2013
- Interaction of allergy history and antibodies to specific varicella‐zoster virus proteins on glioma riskInternational Journal of Cancer, 2013
- A Better Coefficient of Determination for Genetic Profile AnalysisGenetic Epidemiology, 2012